The recent trial flop for Ztalmy, this time in tuberous sclerosis complex (TSC)-associated seizures, leaves the company in a ...
Marinus Pharmaceuticals (MRNS) stock was downgraded at TD Cowen and Truist after a Phase 3 failure for lead asset, ganaxolone ...
Cantor Fitzgerald analyst Charles Duncan lowered the firm’s price target on Marinus Pharmaceuticals (MRNS) to $4 from $13 and keeps an ...
Fintel on MSN1d
Jefferies Downgrades Marinus Pharmaceuticals (MRNS)Fintel reports that on October 25, 2024, Jefferies downgraded their outlook for Marinus Pharmaceuticals (NasdaqGM:MRNS) from ...
Marinus Pharmaceuticals stock plummeted after disappointing data from the Phase 3 TrustTSC trial of ganaxolone for seizures ...
RBC Capital lowered the firm’s price target on Marinus Pharmaceuticals (MRNS) to $1 from $3 and keeps a Sector Perform rating on the ...
Marinus Pharmaceuticals shares plunged nearly 80% to a new all-time low on Thursday after the pharmaceutical company said it is cutting jobs and exploring strategic options following the failure of ...
The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, AbbVie expanded a ...
Marinus said it will discontinue development of the drug, ganaxolone, and take further steps to reduce costs, including job ...
MarketBeat on MSN12d
Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?Detailed price information for Marinus Pharma CS (MRNS-Q) from The Globe and Mail including charting and trades.
Marinus Pharmaceuticals has reported that the Phase III TrustTSC trial of oral ganaxolone in treating seizures linked to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback